NCT04494945Recruiting
Identifying and Caring for Individuals With Inherited Cancer Syndrome
Approaches to Identify and Care for Individuals With Inherited Cancer Syndromes
Source: ClinicalTrials.gov · Last updated 14 Jul 2026
Brief summary (registry, in English)
This trial examines approaches to identify and care for individuals with inherited cancer syndrome. The purpose of this study is to offer no cost genetic testing to the general public. Researchers hope to learn the value of providing broad, public-wide testing for high risk cancer types (like hereditary breast and ovarian cancer or Lynch syndromes) instead of only testing people whose families are known to be high risk.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 27500 (estimated)
- First submitted
- 28 Jul 2020
- Start date
- 9 Mar 2020
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- OHSU Knight Cancer Institute
- Diseases
- Ovarian cancer
- NCT number
- NCT04494945
What you commit to
- Study type: Interventional
- Planned participants: 27500
- From 9 Mar 2020 to the primary completion date, 31 Dec 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- ALL COHORTS: 18 years of age or older
- Retrospective COHORT A: Per HIPAA waiver, Retrospective Cohort A will not actively consent
- Retrospective COHORT A: Patients may or may not be diagnosed with cancer
- Retrospective COHORT A: Patients have received genetic counseling in the past 5 years
- Retrospective COHORT A: Patients have genetic variants that include BRCA1, BRCA2 and/or Lynch syndrome
- COHORT A: Per Health Insurance Portability and Accountability Act (HIPAA) waiver, Cohort A returns survey as consent
- COHORT A: Patients may or may not be diagnosed with cancer
- COHORT A: Patients have received genetic counseling in the past 1 - 2 years
- COHORT A: Patients have genetic variants that include BRCA1, BRCA2 and/or Lynch syndrome
- COHORT A: INCLUSIVE of no contact list to exclude from Cohort B
- COHORT B: Creation of secure Healthy Oregon Project (HOP) app account
- COHORT B: Consent to this project, either hard or electronic signature
- COHORT B: Consent to the HOP repository, either hard or electronic signature
- COHORT B: Choosing to submit a deoxyribonucleic acid (DNA) sample
- COHORT B: Patients diagnosed with any National Cancer Institute (NCI)-reportable cancers, including ductal carcinoma in situ (DCIS) and/or in situ breast cancer
- COHORT B: Must have had an encounter within past twelve months
- COHORT B: Exclude Cohort A
- COHORT C: Creation of secure Hop app account
- COHORT C: Consent to this project, either hard or electronic signature
- COHORT C: Consent to the HOP repository, either hard or electronic signature
- COHORT C: Choosing to submit a DNA sample
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Providence Portland Medical Center Coordinator of this site? Confirm its status | Portland | United States | Recruiting |
| OHSU Knight Cancer Institute Coordinator of this site? Confirm its status | Portland | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.